Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Recurrence 1Neoplasm Metastasis 1Melanoma 1Glioblastoma 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × verubulin × Clear all
NCT00635557 2011-03-25

Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Myrexis Inc.

Phase 1/2 Unknown
30 enrolled
CNS

Glioblastoma, Recurrence

NCT00609011 2010-08-23

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

Myrexis Inc.

Phase 1/2 Completed
22 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡